GW Pharma (GWPH) Tops Q3 EPS by 80c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GW Pharma (GWPH) PT Trimmed to $175 at Cowen, Bullish on Epidiolex Uptake
November 3, 2020 1:41 PM ESTCowen analyst Phil Nadeau lowered the price target on GW Pharma (NASDAQ: GWPH) to $175.00 (from $180.00) while maintaining an Outperform rating.
despite the price target cut, the analyst notes Epidiolex uptake was ahead of consensus with much room to... MoreGW Pharma (GWPH) Begins Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity
November 3, 2020 7:22 AM ESTGW Pharmaceuticals plc (NASDAQ: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity. Nabiximols, known as Sativex® outside of the U.S. and approved for use to treat MS spasticity in over 25 countries, is a complex botanical medicine formulated from extracts of the cannabis plant administered as an oral spray. Positive results from three previous European Phase 3 clinical studies show nabiximols... More
